Published in J Clin Oncol on December 29, 2008
Bevacizumab and Irinotecan to Treat Brain Tumors | NCT00393094
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology (2009) 3.68
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol (2012) 2.39
Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol (2012) 2.31
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology (2011) 1.80
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2009) 1.65
Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg (2011) 1.62
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med (2015) 1.59
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol (2010) 1.59
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem (2011) 1.50
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol (2010) 1.50
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer (2009) 1.49
Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol (2011) 1.46
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.45
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol (2010) 1.40
Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol (2011) 1.38
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res (2014) 1.35
Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res (2012) 1.35
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) (2013) 1.31
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol (2010) 1.31
Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol (2011) 1.29
Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol (2010) 1.27
Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med (2011) 1.27
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol (2010) 1.26
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol (2014) 1.26
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol (2013) 1.25
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2013) 1.25
Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol (2014) 1.24
Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol (2011) 1.24
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol (2014) 1.23
Angiogenesis as a therapeutic target in malignant gliomas. Oncologist (2009) 1.23
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol (2011) 1.23
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics (2009) 1.22
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol (2015) 1.20
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol (2010) 1.19
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res (2013) 1.18
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol (2014) 1.17
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol (2009) 1.17
Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem (2012) 1.16
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol (2013) 1.16
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol (2012) 1.16
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer (2011) 1.16
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep (2013) 1.16
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol (2014) 1.13
MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging (2012) 1.13
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol (2010) 1.13
Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res (2014) 1.12
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res (2013) 1.12
Antiangiogenic therapy for cancer: an update. Pharmacotherapy (2012) 1.10
Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget (2012) 1.09
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol (2011) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol (2013) 1.07
Vascular endothelial growth factor a inhibition in gastric cancer. Gastric Cancer (2014) 1.07
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol (2010) 1.06
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer (2012) 1.06
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol (2015) 1.06
Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (2011) 1.06
Targeting Aggressive Cancer Stem Cells in Glioblastoma. Front Oncol (2015) 1.05
Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther (2010) 1.05
Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS One (2013) 1.05
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist (2010) 1.05
Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol (2010) 1.05
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol (2014) 1.04
Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Ann Transl Med (2015) 1.04
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol (2012) 1.04
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol (2010) 1.04
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol (2014) 1.03
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol (2012) 1.03
Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci (2014) 1.02
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol (2011) 1.02
Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer (2013) 1.02
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. Int J Clin Oncol (2012) 1.01
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer (2010) 1.01
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol (2015) 1.00
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol (2004) 3.25
Factors influencing survival in high-grade gliomas. Semin Oncol (2003) 2.93
Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol (2003) 2.64
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg (1977) 2.39
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res (1991) 1.46
Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg (1992) 1.43
Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol (2001) 1.39
Glioma in the elderly. Curr Opin Oncol (2006) 1.26
Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol (2005) 1.21
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet (2007) 8.68
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA (2004) 4.82
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell (2009) 3.89
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res (2009) 3.58
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann Intern Med (2008) 3.34
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 2.51
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Pathophysiology of persistent syringomyelia after decompressive craniocervical surgery. Clinical article. J Neurosurg Spine (2010) 2.49
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res (2009) 2.42
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Crash and risky driving involvement among novice adolescent drivers and their parents. Am J Public Health (2011) 2.25
Hypo-functional SLC26A4 variants associated with nonsyndromic hearing loss and enlargement of the vestibular aqueduct: genotype-phenotype correlation or coincidental polymorphisms? Hum Mutat (2009) 2.25
Neurofibromatosis type 2. Lancet (2009) 2.24
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res (2008) 2.22
Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res (2007) 2.21
HDAC inhibitors in cancer care. Oncology (Williston Park) (2010) 2.20
Ligation of intersphincteric fistula tract: early results of a pilot study. Dis Colon Rectum (2012) 2.18
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res (2008) 2.16
Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner. J Urol (2006) 1.96
Assessing surrogates as trial endpoints using mixed models. Stat Med (2005) 1.94
Primary central nervous system lymphoma: time to ask the question. J Clin Oncol (2002) 1.92
Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine (2012) 1.92
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest (2004) 1.85
Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther (2004) 1.80
The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev (2007) 1.80
beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene (2004) 1.79
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
Differences in risk factors for recurrent versus incident preterm delivery. Am J Epidemiol (2015) 1.78
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med (2002) 1.74
Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control (2003) 1.73
CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res (2009) 1.72
System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner. Magn Reson Med (2004) 1.71
Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res (2009) 1.69
Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res (2006) 1.68
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
The effects of payment method on clinical decision-making: physician responses to clinical scenarios. Med Care (2004) 1.65
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
User-friendly software for the analysis of brain lesions (ABLe). Comput Methods Programs Biomed (2007) 1.63
History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer (2002) 1.62
Predicting in vitro drug sensitivity using Random Forests. Bioinformatics (2010) 1.59
Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg (2012) 1.59
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg (2006) 1.55
Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage (2008) 1.53
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res (2009) 1.53
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res (2003) 1.53
Quantification of brain lesions using interactive automated software. Behav Res Methods Instrum Comput (2002) 1.51
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol (2009) 1.51
West Nile virus: pathogenesis and therapeutic options. Ann Intern Med (2004) 1.51
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab (2011) 1.50
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer (2005) 1.50
The vestibular aqueduct: site of origin of endolymphatic sac tumors. J Neurosurg (2008) 1.49
Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm (2005) 1.48
Normal vision despite narrowing of the optic canal in fibrous dysplasia. N Engl J Med (2002) 1.47
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys (2004) 1.44
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res (2009) 1.44
Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol (2003) 1.44
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.44
Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol Ther (2002) 1.43
Cochlear implantation for hearing loss associated with bilateral endolymphatic sac tumors in von Hippel-Lindau disease. Otol Neurotol (2007) 1.41
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol (2009) 1.41
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res (2009) 1.40
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum (2012) 1.40
Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg (2008) 1.40
Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med (2004) 1.38
Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res (2006) 1.38
Single-trial fMRI shows contralesional activity linked to overt naming errors in chronic aphasic patients. J Cogn Neurosci (2010) 1.38
Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res (2004) 1.37
Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology (2003) 1.36
Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol (2006) 1.35
Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res (2007) 1.34
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33